Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2340/00015555-0576 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effects of epidural esketamine versus sufentanil on labor analgesia and postpartum depression: a retrospective cohort study.
BMC Anesthesiol
January 2025
Department of Anesthesiology, The Third Affiliated Hospital of Zhengzhou University, No. 7, Zhengzhou Kangfufront Street, Zhengzhou, Henan, 450052, China.
Objective: There is a lack of research on epidural esketamine for labor analgesia. The purpose of this research is to compare the efficacy of epidural esketamine and sufentanil on labor analgesia and postpartum depression.
Methods: A total of 187 cephalic full-term parturients with single-fetus vaginal delivery were collected in this retrospective study from Jan 2022 to Jan 2023.
Intelligent Analgesia Management System in Postoperative Pain Management: A Retrospective Analysis.
J Perianesth Nurs
January 2025
Department of Nursing, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China.
Purpose: This study aimed to explore the effect of an intelligent analgesia management system on postoperative pain management and the working mode of acute pain service.
Design: This is a retrospective cohort study.
Methods: A total of 584 patients who underwent laparoscopic abdominal surgery under general anesthesia and voluntarily received intravenous patient-controlled analgesia (PCA) between January 2018 and April 2020 at our hospital were selected.
Efficacy of Fractional CO Laser Therapy in Improving Symptoms and Quality of Life in Women with Refractory Vulvar Lichen Sclerosus: A Prospective Observational Study.
Life (Basel)
December 2024
Instituto Biosanitario de Granada, Ibs, 18012 Granada, Spain.
Lichen sclerosus (LS) is a chronic inflammatory condition predominantly affecting the anogenital region of postmenopausal women. It is associated with considerable aesthetic and functional impairments and an increased risk of squamous cell carcinoma. While high-potency topical corticosteroids remain the cornerstone of treatment, therapeutic options for patients with refractory LS are scarce.
View Article and Find Full Text PDFLebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis.
J Dermatolog Treat
December 2025
Keck School of Medicine at University of California Los Angeles, Los Angeles, CA, USA.
Background: Lebrikizumab monotherapy significantly improved signs and symptoms in patients with moderate-to-severe atopic dermatitis (AD) in phase 3 Advocate1 and ADvocate2 studies.
Objective: To evaluate improvements in patient-reported symptoms and quality-of-life (QoL) measures by Eczema Area and Severity Index (EASI) response categories using pooled Advocate1 and ADvocate2 data (post hoc analysis).
Methods: In the 52-week (W) (16-W induction + 36-W maintenance) double-blind, placebo-controlled ADvocate1 and ADvocate2 studies, patients were randomized (2:1) to receive subcutaneous lebrikizumab 250 mg or placebo every 2 weeks.
Topical Steroid Withdrawal in Atopic Dermatitis: Patient-reported Characterization from a Swedish Social Media Questionnaire.
Acta Derm Venereol
January 2025
Department of Public Health and Clinical Medicine, Dermatology and Venereology, Umeå University, Umeå, Sweden.
Topical steroid withdrawal (TSW) is described as an adverse reaction to topical glucocorticoids (TGCs). A pathophysiological mechanism has not been identified. There are no diagnostic criteria.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!